PRZOOM - /newswire/ - Gland, Switzerland, 2009/08/17 - Nano Bridging Molecules S.A (NBM), a Swiss early stage med-tech company devoted to developing new generation medical implant surface modifications, announced the successful conclusion of the second of three planned financing rounds.

Following oversubscription of the company’s first funding round in 2007 NBM significantly expanded its pre-clinical testing program, embarked on its first dental human clinical trial, recruited key scientific and clinical research staff and relocated its operations to purpose built laboratories and new offices in the Swiss canton of Vaud. Notwithstanding the current economic downturn the company has fully subscribed its second funding round. The funds raised are being used to conclude a 52 week large animal pre-clinical study (one of the largest of its kind conducted in Switzerland), commencement of orthopedic pre-clinical studies and expansion of its ongoing human dental clinical trials with the establishment of additional study centers in each of Europe and the US. The company is working closely with regulatory consultants aiming to have its first CE Marked dental implant surface treatment on the market in Q4 2010 and to achieve first sales in the orthopedics area in 2012.

About Nano Bridging Molecules S.A.

NBM (nbmolecules.com) is an award winning company which owns the global rights to develop, manufacture and market its SurfLink® technology. At the heart of this technology are patented multi-phosphonated molecules which have been developed over a twelve year period by world-leading, multi-disciplinary scientific teams from the University of Geneva and Ecole Polytechnique Fédérale de Lausanne.

Presently patients requiring joint replacement or spinal implant surgery are required to wait for as long as they possibly can before being operated on as a direct consequence of the limited life span of today’s devices and the likelihood they will, at some point, need to be replaced. Covalently bound to implant surfaces prior to surgery, NBM’s SurfLink® molecules facilitate a chemical reaction that naturally fuses treated implant surfaces to the patient’s bone. This gives rise to the exciting prospect of patients, regardless of age, being able to receive SurfLink® treated implants which will provide truly long term if not a lifetime of service.

For more information please contact:
Björn-Owe Aronsson, a founder and CTO for scientific or technical information
T: +41 (0) 22 354 0054 - E: bjorn-owe.aronsson[.]nbmolecules.com.

Neville Drower, CAO and General Counsel in respect of commercial, regulatory or legal matters
T: +41 (0) 22 354 0051 - E: neville.drower[.]nbmolecules.com.

Agency / Source: Nano Bridging Molecules S.A

Availability: All Regions (Including Int'l)

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

Distribution / Indexing: [+]